BPG is committed to discovery and dissemination of knowledge
JOURNAL HOME
Number of total visits
2732157
Number of visits today
958
Number of downloads
2002978
MEMBERSHIP
BPG JOURNALS
Cited by in F6Publishing
For: Ponce-de-León S, Torres M, Soto-Ramírez LE, José Calva J, Santillán-Doherty P, Carranza-Salazar DE, Carreño JM, Carranza C, Juárez E, Carreto-Binaghi LE, Ramírez-Martínez L, la Rosa GP, Vigueras-Moreno R, Ortiz-Stern A, López-Vidal Y, Macías AE, Torres-Flores J, Rojas-Martínez O, Suárez-Martínez A, Peralta-Sánchez G, Kawabata H, González-Domínguez I, Martínez-Guevara JL, Sun W, Sarfati-Mizrahi D, Soto-Priante E, Chagoya-Cortés HE, López-Macías C, Castro-Peralta F, Palese P, García-Sastre A, Krammer F, Lozano-Dubernard B. Safety and immunogenicity of a live recombinant Newcastle disease virus-based COVID-19 vaccine (Patria) administered via the intramuscular or intranasal route: Interim results of a non-randomized open label phase I trial in Mexico. medRxiv 2022:2022. [PMID: 35169806 DOI: 10.1101/2022.02.08.22270676] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Chia TRT, Young BE, Chia PY. The Omicron-transformer: Rise of the subvariants in the age of vaccines. Ann Acad Med Singap 2022;51:712-729. [DOI: 10.47102/annals-acadmedsg.2022294] [Reference Citation Analysis]
2 Lee J, Khang D. Mucosal delivery of nanovaccine strategy against COVID-19 and its variants. Acta Pharmaceutica Sinica B 2022. [DOI: 10.1016/j.apsb.2022.11.022] [Reference Citation Analysis]
3 García-Sastre A. Mucosal delivery of RNA vaccines by Newcastle disease virus vectors. Curr Res Immunol 2022;3:234-8. [PMID: 36245642 DOI: 10.1016/j.crimmu.2022.10.001] [Reference Citation Analysis]
4 Madhavan M, Ritchie AJ, Aboagye J, Jenkin D, Provstgaad-Morys S, Tarbet I, Woods D, Davies S, Baker M, Platt A, Flaxman A, Smith H, Belij-Rammerstorfer S, Wilkins D, Kelly EJ, Villafana T, Green JA, Poulton I, Lambe T, Hill AVS, Ewer KJ, Douglas AD. Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial. EBioMedicine 2022;:104298. [PMID: 36229342 DOI: 10.1016/j.ebiom.2022.104298] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 González-Domínguez I, Martínez JL, Slamanig S, Lemus N, Liu Y, Lai TY, Carreño JM, Singh G, Singh G, Schotsaert M, Mena I, McCroskery S, Coughlan L, Krammer F, García-Sastre A, Palese P, Sun W. Trivalent NDV-HXP-S Vaccine Protects against Phylogenetically Distant SARS-CoV-2 Variants of Concern in Mice. Microbiol Spectr 2022;:e0153822. [PMID: 35658571 DOI: 10.1128/spectrum.01538-22] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Fulber JPC, Kamen AA. Development and Scalable Production of Newcastle Disease Virus-Vectored Vaccines for Human and Veterinary Use. Viruses 2022;14:975. [DOI: 10.3390/v14050975] [Reference Citation Analysis]
7 González-domínguez I, Martínez JL, Slamanig S, Lemus N, Liu Y, Lai TY, Carreño JM, Singh G, Singh G, Schotsaert M, Mena I, Mccroskery S, Coughlan L, Krammer F, García-sastre A, Palese P, Sun W. Trivalent NDV-HXP-S vaccine protects against phylogenetically distant SARS-CoV-2 variants of concern in mice.. [DOI: 10.1101/2022.03.21.485247] [Reference Citation Analysis]
8 O’donnell KL, Gourdine T, Fletcher P, Shifflett K, Furuyama W, Clancy CS, Marzi A. VSV-Based Vaccines Reduce Virus Shedding and Viral Load in Hamsters Infected with SARS-CoV-2 Variants of Concern. Vaccines 2022;10:435. [DOI: 10.3390/vaccines10030435] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
Write to the Help Desk
© 2004-2023 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

California Corporate Number: 3537345